Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity.

In the subgroup analysis of the low-purity group (n=69), wTMB could not sufficiently discriminate responders with borderline significance (66.7% vs 27.4%, p=0.050), whereas pTMB had superior predictive ability (83.3% vs 22.0%, p<0.001, figure 4B ). pTMB had higher accuracy than wTMB for predicting the response (area under the curve of 0.61 for wTMB and 0.70 for pTMB).

also in 7,017 other papers